Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.

New Safety and Efficacy Data of a Phase 1-2 Study in Patients with Advanced Renal Cell Carcinoma, Following Vaccination with Fourfold Gene-Modified, Allogeneic Tumor Cells Combined with a DNA-Based Immunomodulator.